OTCMKTS:ELTP Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis $0.23 +0.00 (+0.75%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC FilingsShort Interest About Elite Pharmaceuticals Stock (OTCMKTS:ELTP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elite Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2450-Day Range$0.23▼$0.3952-Week Range$0.22▼$0.69Volume1.87 million shsAverage Volume684,475 shsMarket Capitalization$246.34 millionP/E Ratio5.72Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing oral dosage-form products. The company’s portfolio includes generic and proprietary immediate-release and controlled-release tablets and capsules, with an emphasis on products that use abuse-deterrent or other specialized drug-delivery technologies. Elite has developed and commercialized products in several therapeutic categories, including pain management and other prescription medicines. Its activities include product formulation, development, regulatory support, manufacturing, and partnering or licensing arrangements intended to expand the availability of its products in the United States. Based in Northvale, New Jersey, Elite operates primarily in the U.S. pharmaceutical market. The company is led by Nasrat Hakim, who serves as chairman and chief executive officer. Elite’s business has historically centered on building a portfolio of niche generic and specialty pharmaceutical products while maintaining development and manufacturing capabilities for oral medicines.AI Generated. May Contain Errors. Read More Elite Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreELTP MarketRank™: Elite Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elite Pharmaceuticals. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elite Pharmaceuticals is 5.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Elite Pharmaceuticals is 5.65, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.41.Price to Book Value per Share RatioElite Pharmaceuticals has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Elite Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.28% of the float of Elite Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverElite Pharmaceuticals has a short interest ratio ("days to cover") of 1.55, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elite Pharmaceuticals has recently increased by 2.31%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElite Pharmaceuticals does not currently pay a dividend.Dividend GrowthElite Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentElite Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.Search InterestOnly 1 people have searched for ELTP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.01% of the stock of Elite Pharmaceuticals is held by institutions.Read more about Elite Pharmaceuticals' insider trading history. Receive ELTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTP Stock News HeadlinesElite Pharmaceuticals (OTCMKTS:ELTP) Shares Break Below 200-Day Moving Average - What's Next?September 25, 2026 | americanbankingnews.comElite Pharmaceuticals Earnings Call Highlights Steady GrowthAugust 27, 2026 | theglobeandmail.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 2 at 1:00 AM | Porter & Company (Ad)Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call ...August 13, 2026 | finanznachrichten.deElite Pharmaceuticals to Announce Q1 2027 ResultsAugust 12, 2026 | theglobeandmail.comElite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and ...July 1, 2026 | finance.yahoo.comElite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call TranscriptJune 30, 2026 | seekingalpha.comSee More Headlines ELTP Stock Analysis - Frequently Asked Questions How have ELTP shares performed this year? Elite Pharmaceuticals' stock was trading at $0.4903 at the beginning of 2026. Since then, ELTP shares have decreased by 53.9% and is now trading at $0.2260. How were Elite Pharmaceuticals' earnings last quarter? Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) announced its quarterly earnings results on Thursday, August, 13th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Elite Pharmaceuticals had a net margin of 40.19% and a trailing twelve-month return on equity of 44.58%. Read the conference call transcript. How do I buy shares of Elite Pharmaceuticals? Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elite Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/13/2026Today10/02/2026Next Earnings (Estimated)11/12/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ELTP CIK1053369 Webwww.elitepharma.com Phone(201) 750-2646Fax201-750-2755Employees65Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.04 Trailing P/E Ratio5.69 Forward P/E RatioN/A P/E GrowthN/ANet Income$44.87 million Net Margins40.19% Pretax Margin46.16% Return on Equity44.58% Return on Assets29.54% Debt Debt-to-Equity Ratio0.03 Current Ratio3.76 Quick Ratio2.97 Sales & Book Value Annual Sales$148.87 million Price / Sales1.65 Cash Flow$0.03 per share Price / Cash Flow9.06 Book Value$0.09 per share Price / Book2.53Miscellaneous Outstanding Shares1,077,140,000Free Float921,813,000Market Cap$244.94 million OptionableNot Optionable Beta0.34 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:ELTP) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
